DOI: https://doi.org/10.32776/revbiomed.v32i3.912

A single BNT162b2 dose protects against SARS-CoV-2: A case report of a family cluster of COVID-19.

José Antonio Morales-Contreras, Jesús Arturo Ruiz-Quiñonez, Alberto Roblero-Hernández, Gibran Horemheb-Rubio, Samuel Suarez Mendez

Resumen

Abstract

Background. Coronavirus 2019 (COVID-19) disease is an infectious disease caused by the virus "Severe Acute Respiratory Syndrome Coronavirus 2" (SARS-CoV-2). This virus generated a pandemic in 2020 and has affected millions of people worldwide. Facing the need to prevent its contagion, the vaccine BNT162b2 was approved in December 2020 in Mexico and started administered in healthcare workers.

Case presentation. We presented here, two healthcare workers vaccinated with one single dose of BNT162b2, who lives in a family nucleus with high transmission rate of SARS-CoV-2. These healthcare workers, identified in the manuscript as patient E and F, were asymptomatic and their real-time RT-PCR test for SARS-CoV-2 resulted negative, while  the rest of the family (patients A-D) were SARS-CoV-2 positive. The antibody titers IgG anti-spike of patient F (after the second dose; 1080 Au/mL) turned out greater than patient E (before the second dose; 37.1 Au/mL).

Discussion. To our knowledge this is the first case report of the protective effect of single BNT162b2 vaccine dose in the context of high transmission rates within a family nucleus. Despite changes induced by BNT162b2 in the antibody titers with single or double dose vaccination, a single dose of BNT162b2 showed to be sufficient for immunization of patients against COVID-19.

Referencias

Adil MT, Rahman R, Whitelaw D, Jain V, Al-Taan O, Rashid F, et al. SARS-CoV-2 and the pandemic of COVID-19. Postgrad Med J. 2021;97(1144):110-116. https://doi.org/10.1136/postgradmedj-2020-138386

2019-nCoV outbreak is an emergency of international concern. World Health Organization. Available http://www.euro.who.int/en/health-topics/health-emergencies/international-health-regulations/news/news/2020/2/2019-ncov-outbreak-is-an-emergency-of-international-concern (accessed 27 May 2020).

Dhama K, Khan S, Tiwari R, Sircar S, Bhat S, Malik YS, et al. Coronavirus Disease 2019-COVID-19. Clin Microbiol Rev. 2020;33(4):e00028-20. https://doi.org/10.1128/cmr.00028-20

He Q, Mao Q, Zhang J, Bian L, Gao F, Wang J, et al. COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations. Front Immunol. 2021;12:669339. https://doi.org/10.3389/fimmu.2021.669339

US Food and Drug Administration. FDA takes key action in fight against COVID-19 by issuing emergency use authorization for first COVID-19 vaccine [media release]. 11 Dec 2020. http://www.fda.gov.

Vacunación COVID-19 dashboard. [Internet]. Secretaria de salud. 2021 [cited 2021 April 21]. Available from: https://coronavirus.gob.mx/vacunacion-covid/.

Lamb YN. BNT162b2 mRNA COVID-19 Vaccine: First Approval. Drugs. 2021;81(4):495-501. https://doi.org/10.1007/s40265-021-01480-7

Kalimuddin S, Tham CY, Qui M, de Alwis R, Sim JX, Lim JM, et al. Early T cell and binding antibody responses are associated with Covid-19 RNA vaccine efficacy onset. Med (NY). 2021. https://doi.org/10.1016/j.medj.2021.04.003

Favresse J, Bayart JL, Mullier F, Dogné JM, Closset M, Douxfils J. Early antibody response in healthcare professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2). Clin Microbiol Infect. 2021; S1198-743X(21)00224-X. https://doi.org/10.1016/j.cmi.2021.05.004

Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-2615. https://doi.org/10.1056/NEJMoa2034577

Sahin U, Muik A, Vogler I, Derhovanessian E, Kranz LM, Vormehr M, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. medRxiv. 2020. https://doi.org/10.1038/s41586-021-03653-6

Padoan A, Dall'Olmo L, Rocca FD, Barbaro F, Cosma C, Basso D, et al. Antibody response to first and second dose of BNT162b2 in a cohort of characterized healthcare workers. Clin Chim Acta. 2021;519:60-63. https://doi.org/10.1016/j.cca.2021.04.006

Krammer F, Srivastava K, Alshammary H, Amoako AA, Awawda MH, Beach KF, et al. Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. N Engl J Med. 2021;384(14):1372-1374. https://doi.org/10.1056/NEJMc2101667

Blain H, Tuaillon E, Gamon L, Pisoni A, Miot S, Picot MC, et al. Spike Antibody Levels of Nursing Home Residents With or Without Prior COVID-19 3 Weeks After a Single BNT162b2 Vaccine Dose. JAMA. 2021;325(18):1898-1899. https://doi.org/10.1001/jama.2021.6042

Tauzin A, Nayrac M, Benlarbi M, Gong SY, Gasser R, Beaudoin-Bussières G, et al. A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responses. bioRxiv : the preprint server for biology. 2021; 100290. https://doi.org/10.1101/2021.03.18.435972

DOI: https://doi.org/10.32776/revbiomed.v32i3.912

Enlaces refback

  • No hay ningún enlace refback.